I thought it was safe to dip a toe in after the last raise. Still Piranha in the water. Now we likely have to contend with Q4 tax loss selling starting mid Nov. UGHHHHHH
Kirk does not care a lick about dog breath enhancers or their sales potential. He buys things either based on IP, a strategic asset(look at FSCS), or some perceive expertise within the company(maybe ZIOP). Kirk is building a lego set of small companies which may over time support one another and ultimately benefit the parent(Intrexon). People are beginning to question the magic as evidenced by the two extremely dilutive raises recently in the aforementioned 2 stocks. I think Dr. Reed/Mr. Kirk wil change the world. The only unknown is if it will take 2 years or 10.
I think our end of day "sell off" occurred on a total of 300 whopping shares of trading volume. Likely just someone with an axe to grind (mit jdm. ein Hühnchen zu rupfen haben) trying to play games by marking the close.
Insane valuation given approval, Prosl IP win, and recent assurance of listing. My be remains that these guys show us sales prior to year end. I am also hoping that we see action of the Tauropharm IP issue.
Bottom line: Time to push forward------- perfection is the enemy of progress.
That is the hard part---trying to ascertain which of the children will be favored. We assume Intrexon(the parent) will win in the end if a few of the ECCs work out.
FCSC, ZIOP both did pretty dilutive deals over the past month or so. Perhaps we are trading down based on a potential offering? Such is the life of a biotech investor : (
Kirk needs a win. None of the ECCs are anywhere near a salable product. I own ZIOP, a little SYN and am thinking about putting a small wager here. Timing is likely pretty safe since dilutive raise just occurred so they should not need cash for a bit.
You are being silly. This is but one of many ECCS for Intrexon. Kirk already controls the company. Why the heck would he opt to "take it out". ????????
I BELIEVE THE TAUROPHARM PRODUCT IS NOT FORMULATED OPTIMALLY FOR USE IN THE DIALYSIS SPACE. (sorry cap lock) It would be interesting to know the mix between oncology sales and dialysis. Either way, these guys have been stealing for years. It is time to fire the shot across the bow and see if they offer to parlay.
You should a least wait for the Nov. CC. Hopefully CEO Milby enlightens as to the progress of his sales efforts and a few other items.
Steve, I really think it will. We all just need to be patient for a bit longer. I add a few shares each week. This is stunningly undervalued IF IF IF Milby and Co. can show us any traction on the sales front. Hopefully the call is informative on all fronts(Sales, US trial, Partnering, IP issues).